After proteasome inhibitors and immunomodulatory drugs (IMiDs), could monoclonal antibodies be the next “blockbuster” class of drug for multiple myeloma? Dr. Thomas Martin, a myeloma expert and a key clinical investigator in immunotherapy, says yes. This targeted approach to therapy, which identifies a pathway in myeloma cells known as CD38, may have the ability to attack tumor cells while leaving healthy cells alone. So where are we with this now? Dr. Martin explains in this video from the 2014 American Society of Clinical Oncology meeting in Chicago, detailing research into the two leading MABs for myeloma, elotuzumab and SAR650984.

Read the transcript |

Dr. Thomas Martin is a blood disorder specialist and associate director of the Myeloma Institute at the UCSF Medical Center

View more programs featuring Dr. Martin |

Get email alerts |

Subscribe on YouTube |
Like on Facebook |
Follow on Twitter |
Like on Google Plus |

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…